A Phase 2 Study on the Safety and Efficacy of the Anti-BAFF-R Monoclonal Antibody, ESG206, in Patients With Systemic Lupus Erythematosus

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
This is a multicenter, randomized, double‐blind, placebo‐controlled Phase II studydesigned to evaluate the efficacy and safety of ESG206 in participants with SystemicLupus Erythematosus (SLE).
Epistemonikos ID: b5f168a74fea13630dbad753990cb3f25016725c
First added on: Aug 12, 2026